Innoviva Inc is a company with a portfolio of royalties healthcare assets... Show more
On March 24, 2025, the Stochastic Oscillator for INVA moved out of oversold territory and this could be a bullish sign for the stock. Traders may want to buy the stock or buy call options. Tickeron's A.I.dvisor looked at 66 instances where the indicator left the oversold zone. In of the 66 cases the stock moved higher in the following days. This puts the odds of a move higher at over .
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where INVA's RSI Indicator exited the oversold zone, of 25 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .
The Momentum Indicator moved above the 0 level on March 26, 2025. You may want to consider a long position or call options on INVA as a result. In of 84 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
The Moving Average Convergence Divergence (MACD) for INVA just turned positive on March 25, 2025. Looking at past instances where INVA's MACD turned positive, the stock continued to rise in of 49 cases over the following month. The odds of a continued upward trend are .
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where INVA advanced for three days, in of 291 cases, the price rose further within the following month. The odds of a continued upward trend are .
INVA may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The 50-day moving average for INVA moved below the 200-day moving average on February 24, 2025. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where INVA declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
The Aroon Indicator for INVA entered a downward trend on March 11, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. INVA’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock slightly better than average.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.621) is normal, around the industry mean (13.948). P/E Ratio (49.667) is within average values for comparable stocks, (66.289). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.930). Dividend Yield (0.000) settles around the average of (0.025) among similar stocks. P/S Ratio (3.698) is also within normal values, averaging (240.137).
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
a biopharmaceutical company
Industry Biotechnology
1 Day | |||
---|---|---|---|
MFs / NAME | Price $ | Chg $ | Chg % |
QFVIX | 24.23 | N/A | N/A |
Pear Tree Polaris Foreign Value Instl | |||
IJEMX | 13.67 | N/A | N/A |
VY® JPMorgan Emerging Markets Equity I | |||
GSCZX | 16.73 | N/A | N/A |
GuideStone Funds Small Cap Equity Inv | |||
ALMZX | 24.59 | N/A | N/A |
Alger MidCap Growth Institutional Z-2 | |||
RGLEX | 23.87 | -0.26 | -1.08% |
American Funds Global Insight R-4 |
A.I.dvisor indicates that over the last year, INVA has been loosely correlated with SGMO. These tickers have moved in lockstep 40% of the time. This A.I.-generated data suggests there is some statistical probability that if INVA jumps, then SGMO could also see price increases.
Ticker / NAME | Correlation To INVA | 1D Price Change % | ||
---|---|---|---|---|
INVA | 100% | +0.23% | ||
SGMO - INVA | 40% Loosely correlated | +0.69% | ||
NAUT - INVA | 35% Loosely correlated | -2.19% | ||
DTIL - INVA | 34% Loosely correlated | -11.00% | ||
RCUS - INVA | 34% Loosely correlated | -1.67% | ||
INSM - INVA | 33% Loosely correlated | -2.51% | ||
More |